Publications & Reports

Fc receptors are major mediators of antibody based inflammation in autoimmunity.

Hogarth PM
Helen McPherson-Smith Laboratory, Austin Research Institute, Heidelberg, VIC, Australia. pm.hogarth@ari.unimelb.edu.au

Abstract

There is now renewed interest in the role of antibodies in autoimmunity. Recent compelling evidence indicates that autoantibodies and the effector mechanisms they induce, for example, Fc receptor activation of leukocytes and/or the complement cascade, are central players in the development of autoimmunity, by perpetuating inflammation and perhaps even regulating the process itself. Of increasing interest are Fc receptors, which have been more closely investigated in the past decade using recombinant proteins, gene deficient mice and mouse models of human disease. These analyses point towards major roles of Fc receptors in antibody hypersensitivity reactions and by extension autoimmune disease, and they reveal opportunities in the development of novel therapeutic approaches in the treatment of autoimmune diseases.

Project

  • New approaches to the treatment of lupus
    Lupus is a neglected severe chronic disease primarily affecting women. We discover the receptor that triggers inflammation caused by immune complexes (ab and antibodies produced in lupus and related diseases like rheumatoid arthritis). Antiphospholipid syndrome a particular complication of lupus but one also found in the broader community also involves immune complex activation of life-threatening blood clotting. We are researching potential new diagnostic and therapeutic approaches targeting the cause of the disease.

Publication

  • Journal: Current opinion in immunology
  • Published: 01/12/2002
  • Volume: 14
  • Issue: 6
  • Pagination: 798-802

Author